CLINICAL_TRIALS ClinicalTrials.gov record update

Camrelizumab Combined With Apatinib and Capecitabine for Patients With Advanced Biliary Tract Cancer: a Phase 2, Single-arm, Prospective Study.

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04720131
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:40:00.079345+00:00
Published At: 2024-01-30T00:00:00+00:00
Record Updated At: 2024-01-30
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Biliary Tract Cancer", "Anti-PD-1 Therapy", "Targeted Molecular Therapy", "Capecitabine"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-01-30"
protocolSection.identificationModule.nctId: "NCT04720131"
protocolSection.identificationModule.officialTitle: "Camrelizumab Combined With Apatinib and Capecitabine for Patients With Advanced Biliary Tract Cancer: a Phase 2, Single-arm, Prospective Study."
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.